About Us Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world. It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve. , Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.

We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients. At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families , we are deeply committed to improving the lives of patients and prioritizing their needs above all else.

We believe in being authentic —leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn , we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit.

Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries. These values are the foundation of our work, empowering us to make a real difference, every day.

The VP, Clinical Development will have direct responsibility as Clinical Lead accountable for clinical development strategy and execution across one or more programs. The successful candidate will be a highly credible physician leader, a strong people manager, and a trusted thought partner to the program GPH, other VP-CDLs, the CMO, the CEO, and Executive Committee members.

Key Responsibilities

Danicamtiv Program – Clinical Lead Serve as the Clinical Lead for the Danicamtiv program, with end-to-end accountability for clinical strategy and execution, including protocol development and approval and regulatory interactions. Lead the Danicamtiv Clinical Strategy Team (CST) with cross-functional leadership in development and execution of the Danicamtiv clinical development plan. Own clinical development plans, and protocol design, with critical input for indication selection and target product profile (TPP) development for Danicamtiv.

Lead clinical decision-making based on emerging data, benefit–risk assessments and evolving regulatory interactions and expectations. Act as the primary clinical development point of contact for regulatory interactions, investigators, and key opinion leaders related to the Danicamtiv program. Partner closely with colleagues from Clinical Operations, Biometrics, Regulatory, and Medical Affairs to ensure seamless oversight and execution of clinical trials across the Danicamtiv program.

Executive External Engagement Act as a senior clinical representative for discussions with the Kardigan Executive Committee, as needed. Present clinical strategy, study progress, and risks to internal leadership and, when needed, to the Kardigan Executive Committee and Board of Directors. Represent the Kardigan clinical development function externally at scientific meetings, advisory boards, and interactions with Key Opinion Leaders, related to the Danicamtiv programs and potentially for other drug programs, as well.

Qualifications

MD (or equivalent medical degree); board certification and clinical practice experience in cardiology strongly preferred.

Vice President, Clinical Development, Danicamtiv (DANI)